Alabama
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
California
Stanford; Stanford Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Colorado
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Florida
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Georgia
Atlanta; The Emory Clinic
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Illinois
Chicago; Feinberg School of Medicine
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Indiana
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Iowa
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Louisiana
New Orleans; Tulane University Health Science Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Massachusetts
Boston; Boston Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Michigan
Detroit; Henry Ford Health System
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Nebraska
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
New York
New York; New York University Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
New York; Biomedical Research Alliance of New York
Mycosis Fungoides- Cutaneous t-cell lymphoma
New York; Memorial Sloan Kettering Cancer Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Syracuse; SUNY Upstate Medical University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
North Carolina
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Ohio
Cleveland; University Hospital of Cleveland
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Columbus; Ohio State University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Oregon
Portland; Oregon Health & Science University
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Pennsylvania
Philadelphia; University of Pennsylvania Health System
A phase II trial to evaluate the safety and effectiveness of nitrogen mustard (NM) 0.02% ointment formulations in patients with stage I or IIA mycosis fungoides (MF)
Philadelphia; University of Pennsylvania Health System
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Tennessee
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
Texas
Dallas; Baylor University Medical Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Houston; MD Anderson Cancer Center
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplaston A10 And AS2-1 In Patients With Mycosis Fungoides - Sezary Syndrome
Various Cities; Research Center
T-Cell Lymphoma Study CLBH589B2201
International
Lyoin, France; Hôpital de L’Hôtel Dieu
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Nice, France; Hôpital Archet II
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Paris Cedex 10, France; Hôpital Saint-Louis
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Pierre Bénite, France; Centre Hospitalier Lyon Sud
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Essen, Germany; University of Essen, Dept. of Dermatology
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Kiel, GERMANY; University of Kiel
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Minden, Germany; Akademisches Lehrkrankenhaus der medizinischen Hochschule Hannover
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Würzburg, Germany; University of Würzburg
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Bologna, ITALY; Instituto di Ematologia e Oncologia Medica L. & A. Seragnoli
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Florence, ITALY; University of Florence Medical School Department of Dermatology
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Rome, ITALY; IDI-IRCCS
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Turin, Italy; University of Turin
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Madrid, SPAIN; Hospital Universitario de la Princesa
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
Madrid, SPAIN; Maternidad Planta Baja
If you have mycosis fungoides type CTCL and have experienced treatment failure or lack of tolerance with systemic or skin directed treatments you may be eligible for this clinical trial.
